Viewing Study NCT06790966

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:32 PM
Ignite Modification Date: 2026-02-04 @ 4:17 AM
Study NCT ID: NCT06790966
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-11
First Post: 2025-01-14
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sponsor: PDS Biotechnology Corp.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Recurrent Head and Neck Cancer View
None Metastatic Head and Neck Cancer View
None HPV Positive Oropharyngeal Squamous Cell Carcinoma View
None Neoplasms, Head and Neck View
None Unresectable Head and Neck Squamous Cell Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Head and neck cancer View
None Head and neck neoplasms View
None Neoplasms, squamous cell View
None Squamous cell carcinoma of the head and neck View
None Head and neck squamous cell carcinoma View
None Recurrent Head and Neck cancer View
None Metastatic Head and Neck Cancer View
None Immuno-oncology therapy View
None Human papillomavirus-16 View
None Cancer Vaccines View
None HNSCC View
None Oropharyngeal squamous cell carcinoma View
None HPV View
None Programmed cell death ligand 1 View
None PD-L1 View
None Immune checkpoint inhibitor View
None Immune checkpoint inhibitors View
None Immunotherapy View
None Squamous cell cancer View
None Pembrolizumab View
None Antineoplastic Agents, Immunological View